WARNING: ANAPHYLACTIC REACTIONS
Anaphylactic reactions to ELOXATIN have been reported, and may occur within minutes of ELOXATIN administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms of anaphylaxis [see Warnings and Precautions].
ELOXATINâ¢ (oxaliplatin for injection) is an antineoplastic agent. Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a leaving group.
ELOXATIN, used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum.
Media Articles Related to Eloxatin (Oxaliplatin)
No Increased Risk of Colorectal Cancer in Older-Onset IBD
Source: Medscape Allergy & Clinical Immunology Headlines [2016.08.18]
A new diagnosis of inflammatory bowel disease (IBD) in individuals over age 60 does not increase the risk of developing colorectal cancer, although patients may be at increased risk for hematological cancers, say researchers based in France.
Reuters Health Information
Genetic cause of 15 percent of colorectal cancer diagnoses identified
Source: Colorectal Cancer News From Medical News Today [2016.07.20]
Findings open up 'precision medicine' approach to prevention, diagnosis and treatment.
Internal radiation therapy: Better response in metastatic colorectal cancer patients
Source: Colorectal Cancer News From Medical News Today [2016.07.10]
New analysis shows patients with metastatic colorectal cancer treated with radiation therapy show better response than those receiving chemotherapy alone.
Colorectal cancer: Pivotal Phase III data for Xilonix presented
Source: Clinical Trials / Drug Trials News From Medical News Today [2016.07.05]
XBiotech Inc., developer of next-generation True Human™ antibody therapies, has presented positive results from a pivotal Phase III trial of Xilonix™, the company's lead monoclonal...
Anti-PD-L1 immunotherapy shows response in microsatellite-stable metastatic colorectal cancer in combination with MEK inhibition
Source: Colorectal Cancer News From Medical News Today [2016.07.04]
Anti-PD-L1 immunotherapy may achieve a response in patients with microsatellite-stable metastatic colorectal cancer if combined with a MEK inhibitor, according to phase I data presented at the ESMO...
Published Studies Related to Eloxatin (Oxaliplatin)
Phase III randomized, placebo-controlled, double-blind study of intravenous
calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity
whether calcium/magnesium decreases oxaliplatin-related neurotoxicity... CONCLUSION: This study does not support using calcium/magnesium to protect
Improved time to treatment failure with an intermittent oxaliplatin strategy:
results of CONcePT. 
intended to reduce neurotoxicity and extend the duration of treatment... CONCLUSIONS: An IO dosing schedule had a significant benefit on both TTF and TTP
Phase I drug-interaction study of effects of calcium and magnesium infusions on
oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer
hyperexcitability and acute neurotoxicity symptoms are unclear... CONCLUSIONS: Ca/Mg infusions do not alter the clinical pharmacokinetics of
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. [2011.07.10]
PURPOSE: To investigate oxaliplatin combined with fluorouracil-based chemoradiotherapy as preoperative treatment for locally advanced rectal cancer... CONCLUSION: Adding oxaliplatin to fluorouracil-based preoperative chemoradiotherapy significantly increases toxicity without affecting primary tumor response. Longer follow-up is needed to assess the impact on efficacy end points.
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. [2011.07]
BACKGROUND: When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation of time without toxic effects could be one effective strategy to achieve both of these goals. The COIN trial assessed preplanned treatment holidays in advanced colorectal cancer to achieve this aim... INTERPRETATION: Although this trial did not show non-inferiority of intermittent compared with continuous chemotherapy for advanced colorectal cancer in terms of overall survival, chemotherapy-free intervals remain a treatment option for some patients with advanced colorectal cancer, offering reduced time on chemotherapy, reduced cumulative toxic effects, and improved quality of life. Subgroup analyses suggest that patients with normal baseline platelet counts could gain the benefits of intermittent chemotherapy without detriment in survival, whereas those with raised baseline platelet counts have impaired survival and quality of life with intermittent chemotherapy and should not receive a treatment break. FUNDING: Cancer Research UK. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Clinical Trials Related to Eloxatin (Oxaliplatin)
Oxaliplatin in Treating Patients With Metastatic Breast Cancer [Active, not recruiting]
This phase 0/II trial studies the effect of carbon C 14 oxaliplatin in tumor tissue and
blood and the side effects and how well oxaliplatin works in treating patients with
metastatic breast cancer. DNA analysis of tumor tissue and blood samples from patients
receiving carbon C 14 oxaliplatin may help doctors predict how well patients will respond to
treatment with oxaliplatin. Drugs used in chemotherapy, such as oxaliplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing.
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma [Completed]
Studies done in the laboratory have demonstrated beneficial effects of ON 01910. Na, a new,
unapproved drug, when it is used in combination either irinotecan and oxaliplatin, two
approved, extensively used anti-cancer drugs. In these laboratory studies, mice implanted
with cells (Bel-7402 cells) that came from a human tumor were used as a model of liver
cancer. In mice that were not treated, the Bel-7402 cells formed very large tumors. In mice
that were treated with ON 01910. Na, irinotecan or oxaliplatin alone, growth of tumors was
reduced compared to the untreated group. When a combination of ON 01910. Na and irinotecan or
of ON 01910. Na and oxaliplatin was used to treat the mice, tumor growth was completely
inhibited. Another observation in these studies was that toxicity did not increase when the
combinations were used. These results and similar results from other studies support the
hypothesis that a combination of ON 01910. Na and irinotecan or of ON 01910. Na and
oxaliplatin would be an effective and tolerable treatment for liver and other types of
The primary objective of this phase 1 study is to find out what doses of ON 01910. Na in
combination with either irinotecan or oxaliplatin are safe and tolerable in patients with
liver and other types of cancer.
Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer [Recruiting]
The purpose of this study is to determine whether Monosialotetrahexosylganglioside sodium
injection can relieve the neurotoxicity caused by oxaliplatin in GI cancer.
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL [Completed]
1. Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of
oxaliplatin in combination with fludarabine, Ara-C and rituximab in patients with
Richter's transformation, prolymphocytic leukemia (PLL), or refractory/relapsed B-cell
chronic lymphocytic leukemia (CLL).
2. Assess the complete response (CR) and partial response (PR) rate to combination therapy
of oxaliplatin, fludarabine, Ara-C and rituximab in patients with Richter's
transformation, PLL or refractory/relapsed B-cell CLL.
3. Determine the safety and toxicity profile of combination therapy of oxaliplatin,
fludarabine, Ara-C and rituximab in patients with Richter's transformation, PLL or
refractory/relapsed B-cell CLL.
1. Determine the duration of response, failure-free survival, and overall survival.
2. Determine the incidence of infections (bacterial, fungal, and viral) in patients with
Richter's transformation, prolymphocytic leukemia or refractory/relapsed B-cell CLL
treated with rituximab, oxaliplatin, fludarabine and Ara-C; monitor immune parameters
such as T cell counts and immunoglobulin levels; and monitor Epstein-Barr virus (EBV)
3. Characterize the pharmacodynamics of oxaliplatin in leukemia cells with respect to
total adduct formation, cross-link formation and excision deoxyribonucleic acid (DNA)
responses. Compare these parameters in cells from the same patient after treatment
with oxaliplatin in combination with fludarabine and Ara-C.
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab [Active, not recruiting]
The goal of this clinical research study is to find the highest tolerable dose of the
combination of oxaliplatin and capecitabine with or without bevacizumab that can be given to
patients with advanced cancer that has spread to the liver. The safety of these drug
combinations will also be studied.
Reports of Suspected Eloxatin (Oxaliplatin) Side Effects
Abdominal Pain (18),
Renal Failure Acute (12),
Asthenia (12), more >>
Page last updated: 2016-08-18